Proactive - Interviews for investors

Lancaster Resources Vice President of Engineering Andrew Watson joined Steve Darling from Proactive to discuss the company's upcoming exploration plans for its uranium-prospective Catley Lake and Centennial East properties in the Athabasca Basin of Saskatchewan, Canada. These properties, covering approximately 8,117 hectares, are strategically located adjacent to Cameco's Centennial deposit claims.

Watson outlined that the company's initial plans include detailed surface outcrop mapping using hyperspectral data to identify vegetation stress indicative of subsurface uranium. The exploration efforts will also involve acquiring high-resolution optical imagery and purchasing corrected imagery for hyperspectral analysis.

The results from the hyperspectral imaging (HSI) will be used to prioritize and focus follow-up field geology, geochemical sampling, and geophysics programs. These follow-up programs will concentrate on areas identified by the HSI that show positive indications for uranium. Upon completion of the fieldwork and geophysics program, target locations will be identified for an initial drilling program planned for Q4 2024.

This comprehensive exploration approach underscores Lancaster Resources' commitment to advancing its uranium prospects in the highly prospective Athabasca Basin, aiming to uncover substantial uranium resources adjacent to known deposits.

#proactiveinvestors #lancasterresourcesinc #cse #lcr @otcqb #lanrf

#UraniumExploration #CleanEnergy #EnergyTransition #AthabascaBasin #Saskatchewan #CentennialEast #KariLake #AdvancedTechnologies #Geophysics #HyperspectralImaging #ArtificialIntelligence #MachineLearning #Mining #ResourceExploration #EnergySector #DrillingProgram #GeologicalModels #SustainableEnergy #ExplorationStrategy#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share promising news about the company's ultra-broad-spectrum antiviral, NV-387. The antiviral was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.

Dr. Diwan explained that the lung protection provided by NV-387 is particularly important, as severe cases of respiratory viral infections, which often lead to hospitalization and fatalities, typically involve extensive lung damage. In the study, NV-387 oral treatment resulted in only about 31% lung infiltration by immune system cells, while NV-387 intravenous treatment showed an even lower infiltration rate of about 22%. In comparison, the lungs of infected untreated animals exhibited a high infiltration rate of 68%. These findings indicate that NV-387 significantly protects the lungs of Balb/c mice lethally infected with the Influenza A H3N2 virus. Moreover, NV-387 treatment resulted in a significantly greater survival improvement compared to three approved influenza drugs. This remarkable outcome highlights the potential of NV-387 as a powerful therapeutic option for treating severe influenza infections and possibly other respiratory viral infections.

Further, in this study, NV-387 was also found to protect the lungs of the infected animals from viral damage as well as immune system damage, supporting a strong antiviral effect. These results have arrived just as the bird flu H5N1 threat potential has increased significantly due to its spread into several mammalian species. While dairy cattle have suffered relatively mild infections, some other mammals, particularly cats on farms, have died of brain infection with this virus. Only four human cases have occurred so far, with one person dying in Mexico, while the three other cases, all in the USA, have recovered.

This highlights the urgency and potential impact of NV-387 in addressing not only current viral threats but also emerging ones, making it a critical development in the field of antiviral therapies.

#proactiveinvestors #nanoviricidesinc #nyseamerican #nnvc #biotec

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

D’Amico International Shipping CEO Carlos Balestra di Mottola joined Steve Darling from Proactive from our OTC studio in New York City to discuss the company's operations and future strategies. Specializing in product tankers that primarily transport refined petroleum products, D’Amico International Shipping currently operates a fleet of 33 vessels, with plans to expand to 34 by July 2024. This fleet comprises 25 owned vessels, three bareboat chartered vessels, and five time-chartered vessels.

Operating on a global scale with offices in Singapore, London, and New York, D’Amico International Shipping has been listed on the Milan Stock Exchange since 2007. The product tanker sector, which was the last among shipping sectors to recover post-Covid, has recently seen significant improvement. This recovery has been driven in part by disruptions such as the Ukraine war and the Suez Canal incidents, which extended voyage times.

Despite being content with its current fleet size, D’Amico is focused on modernizing its fleet by replacing older vessels with new, more efficient ones. The company has ordered four new ships, which are scheduled for delivery between 2027 and 2028. Alongside this fleet modernization, D’Amico has shifted its market strategy to favor spot markets while securing profitable long-term contracts to ensure future earnings visibility.

Expansion into the US market is a key focus for D’Amico, with the company increasing its visibility and engagement with US investors. This effort reflects a broader international investor interest, as evidenced by recent shareholder actions.

These strategic moves underscore D’Amico International Shipping's commitment to enhancing its global operations and ensuring sustained growth and profitability in the dynamic shipping industry.

#proactiveinvestors #d’Amicointernationalshippings.a #otcqx #dmcof

ProductTankers #GlobalShipping #FleetExpansion #MaritimeIndustry #ShippingSector #PetroleumTransport #TradeDisruptions #ModernFleet #USMarket #StockExchange #MaritimeInvestment #GlobalOperations #EfficientShipping #VesselReplacement #LongTermContracts #ShippingMarkets #InvestorEngagement #ShippingGrowth #MaritimeBusiness#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 patients in a randomized, double-masked, placebo-controlled study. OK-101, developed using a membrane-anchored-peptide technology, is a novel long-acting drug candidate designed to treat dry eye disease. It has shown anti-inflammatory and pain-reducing efficacy in mouse models of dry eye disease and corneal neuropathic pain.

Jacobs highlighted that the findings include a statistically significant and durable reduction in ocular pain and a statistically significant improvement in Tear Film Break-Up Time throughout the study, which is a clinically important endpoint. Additionally, multiple symptomatic improvements were observed through both data obtained from patient clinic visits and daily symptom diaries.

Jacob explained that OK-101 targets a receptor called Chemerin 23, present on both immune and nerve cells, including those in the spinal cord and ocular nerves. Preclinical animal studies indicated that OK-101 could reduce neuropathic pain, which can be particularly severe and debilitating in affected patients. The company is preparing to launch a Phase II trial for OK-101 specifically targeting neuropathic corneal pain.

This trial will be a placebo-controlled, randomized study involving 48 patients diagnosed with ocular nerve damage through confocal microscopy, with top-line data anticipated by mid-2025.The significance of this development is underscored by the lack of FDA-approved treatments for neuropathic corneal pain, a condition recognised by the National Organization of Rare Diseases. The upcoming trial aims to fill this therapeutic gap, potentially offering relief to patients suffering from this excruciating condition.

#proactieinvestors #okyopharmalimited #nasdaq #okyo

#GaryJacob, #DryEyeDisease, #OK101, #ClinicalTrials, #NeuropathicPain, #OcularHealth, #PharmaceuticalResearch, #FDAApproval, #MedicalInnovation, #HealthUpdates, #BiotechNews, #PatientCare, #PhaseIITrail, #TopLineData, #Chemerin23, #NerveDamage, #RareDiseases, #PlaceboControlled, #EyeResearch#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Ocean Power Technologies CEO Philipp Stratmann joined Steve Darling from Proactive to announce that the company has been selected as a preferred supplier for a PowerBuoy equipped with Merrows, its Artificial Intelligence-capable Maritime Domain Awareness Solution. This selection is for an immediate delivery opportunity in the Middle East. The contract, once finalized, is expected to generate revenues in the current quarter. The company had previously announced the completion of engineering for Merrows to operate in hot climates.

Stratmann highlighted that this development is another example of the company's growth in its PowerBuoy business. He emphasized that the Middle East presents significant opportunities for Merrows and the potential to integrate additional Wave Adaptive Modular Vessels (WAM-Vs) into their operations.

This strategic move underscores Ocean Power Technologies' commitment to expanding its market presence and leveraging its advanced maritime technologies to meet the growing demand in the Middle East.

#proactiveinvestors #oceanpowertechnologiesinc #nyseamerican #optt

#OffshoreEnergy, #NationalSecurity, #MiddleEastExpansion, #PreferredSupplier, #BuoyTechnology, #EdgeComputing, #ArtificialIntelligence, #SubSaharanAfrica, #PacificExpansion, #CommercialTraction, #RenewableEnergy, #AutonomousVehicles, #EnvironmentalSustainability, #CleanEnergy, #GreenTechnology, #MarineTechnology, #PhillipStratmann, #EnergySolutions, #GlobalMarket

#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

European Green Transition PLC (AIM:EGT) CEO Aiden Lavelle joined Proactive's Stephen Gunnion to discuss the company's milestones in 2023 as it prepared to list on AIM, as well as future plans.

Lavelle highlighted the successful IPO in April 2023, raising £6.5 million. He discusses the acquisition of the Olserum Rare Earth project and its promising potential, mentioning the encouraging rock and general sampling results at the Djupedal prospect, which shows significant rare earth oxide percentages.

Lavelle also outlined the company's low-cost drilling program aimed at exploring the Djupedal prospect further and testing a new exploration model developed by the team. This initiative aims to prove the concept of surface mineralisation and attract partners to monetize the asset.

Furthermore, Lavelle talked about other assets in European Green Transition's portfolio, such as the Limni Tailings Recycling Project in Cyprus and the Altan Peatland Restoration and Carbon Credit Project in Ireland. The former focuses on copper recycling and potential solar energy generation, while the latter aims at rewetting, peatland restoration, and selling carbon credits, tapping into a market projected to reach €50 billion by 2030.

Lavelle emphasised the company's strategy to capitalize on Europe's green energy transition by identifying and developing green economy assets.

For more insightful interviews and updates, visit Proactive's YouTube channel, give this video a like, subscribe to the channel, and enable notifications for future content.

#EuropeanGreenTransition #AidenLavelle #GreenEnergy #RareEarthMetals #IPO2023 #SustainableProjects #CarbonCredits #Recycling #RenewableEnergy #InvestingInGreen #ProactiveInterviews #GreenEconomy #FutureOfEnergy

London stocks have failed to make any movements this morning as the lack of company or macroeconomic updates added to the ongoing election campaign, leaving the markets in a state of purgatory.

Saga shares edged higher after it reported further strong trading for its ocean cruise business despite warning that the insurance market remains “challenging”.

Overall, the provider of services to the over-50s said, trading was in line with expectations, with ocean and river cruises both having seen load factors increase by 83% and 78% respectively compared to last year.

Shein is closing in on its eagerly-awaited London IPO after reports revealed it filed papers with UK market regulators earlier this month. A listing is expected to take place later this year.

Meanwhile, AstraZeneca shares have shrugged off disappointing news on an advanced lung cancer trial of its Imfinzi immunotherapy. Phase III trials showed the drug did not achieve statistical significance for its primary endpoint of disease-free survival compared to a placebo in early-stage non-small cell lung cancer.

#proactiveinvestors #marketreport #ftse #ftse100 #footsie #saga #astrazeneca #imfinzi #shein #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon joined Proactive's Stephen Gunnion with details of a £750,000 contract from a global bluechip construction company. This order was secured due to the company's innovative fire barrier solutions, which save clients money and time by avoiding traditional fire-stopping methods.

Deacon emphasised that this initial contract is likely to lead to more work with the same customer and highlighted the potential market size of £50 billion in passive fire protection.

He also mentioned the progress of a £600,000 contract for fire protection in Salford and expressed optimism about further opportunities.

Deacon said the retrofit market, driven by new safety regulations, presents substantial growth potential with an estimated 33,000 buildings requiring updates.

To capitalise on this market, Light Science Technologies is ramping up efforts, including the appointment of Sean Tasker as the new managing director for the division. Deacon shared that the company is handling increasing inquiries and aims to convert these into contracts, expecting significant growth and improved margins across all divisions.

Visit Proactive's YouTube channel for more videos, and don't forget to like this video, subscribe to the channel, and enable notifications for future content.

#LightScienceTechnologies #SimonDeacon #PassiveFireProtection #ConstructionInnovation #RetrofitMarket #BuildingSafety #FireSafetySolutions #CEOTalks #BusinessGrowth #ProactiveInvestors #ProactiveInvestors #investingtips #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Downing Fund Managers Mike Clements and Pras Jeyanandhan speak to Proactive's Stephen Gunnion about opportunities offered by the VT Downing European Unconstrained Income Fund.

Clements told Proactive the fund is a concentrated Europe ex-UK product, typically focusing on small and mid-cap companies.

Clements and Jeyanandhan explained why Europe is attractive to investors right now, highlighting that European markets are at their most affordable in 15 years, particularly for small caps. They also discuss their approach to identifying opportunities, including contrarian plays and detailed value chain analysis.

Jeyanandhan gave an example of a successful investment in InPost, a company revolutionising parcel delivery in Poland and expanding rapidly in the UK and France. Clements adds another example from the offshore wind industry, where they identified a bottleneck in the installation process, leading to investment in Danish company Cadeler.

For investors looking for diversification and unique stock-picking opportunities, the VT Downing European Unconstrained Income Fund provides a blend of contrarian investments and value chain insights. As Clements states, "clients use us essentially as a stock picking fund" with a diverse all-cap portfolio.

Don't forget to visit Proactive's YouTube channel for more insightful videos, and remember to like, subscribe, and enable notifications for future content.

#InvestmentInsights #EuropeanMarkets #DowningFundManagers #SmallCapInvesting #StockPicking #ContrarianInvesting #ValueChainAnalysis #VTDowningFund #ProactiveInvestors #Finance #MarketAnalysis #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Immunic Inc CEO Daniel Vitt speaks to Proactive's Stephen Gunnion about the rise of autoimmune diseases such as multiple sclerosis (MS) and celiac disease, attributing this trend to environmental and diagnostic factors. Vitt highlighted how better diagnostic tools have identified more cases, previously undetected.

Vitt discussed Immunic’s lead asset for treating MS, emphasizing the urgent need for treatments addressing disability worsening, which current drugs do not fully cover. He explained the unique attributes of the oral small molecule vidofludimus calcium, developed by Immunic, which has a triple activity - anti-inflammatory, antiviral, and neuroprotective properties. This combination could address the unmet need in MS treatments, particularly in non-relapsing patients.

Vitt also updated on the recruitment progress for Immunic's phase 3 trials in relapsing MS, stating the trials are on schedule. He expressed optimism about the potential of their phase 2 results in progressive MS expected in April 2025, describing it as a possible game-changer.

Visit Proactive's YouTube channel for more insightful interviews. Don’t forget to like this video, subscribe to our channel, and enable notifications for future content.

#ImmunicInc #AutoimmuneDiseases #MultipleSclerosis #MSResearch #VidofludimusCalcium #Biotech #HealthcareInnovation #ClinicalTrials #Neuroprotection #ProactiveInterviews

#ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews